Q4 Earnings Roundup: ABT, GD, KMB & More
https://www.zacks.com/stock/news/2215065/q4-earnings-roundup-abt-gd-kmb-more?cid=CS-ZC-FT-ahead_of_wall_street-2215065
Jan 24, 2024 - A spot-check of early morning Q4 reports show some earnings misses and revenue beats; Tesla and others report after the close.
0
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility
https://www.zacks.com/stock/news/2223400/insulet-s-podd-omnipod-5-gets-ce-mark-for-added-compatibility?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2223400
Feb 08, 2024 - Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.
0
Top Analyst Reports for Microsoft, Amazon.com & Berkshire Hathaway
https://www.zacks.com/commentary/2230125/top-analyst-reports-for-microsoft-amazon-com-berkshire-hathaway?cid=CS-ZC-FT-research_daily-2230125
Feb 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and Berkshire Hathaway Inc. (BRK.B).
0
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact
https://www.zacks.com/stock/news/2237550/abbott-abt-to-reduce-childhood-malnutrition-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237550
Mar 07, 2024 - Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
0
Here's Why Investors Should Retain Abbott (ABT) Stock Now
https://www.zacks.com/stock/news/2243034/here-s-why-investors-should-retain-abbott-abt-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2243034
Mar 19, 2024 - Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
0
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
https://www.zacks.com/stock/news/2246922/abbott-s-abt-assert-iq-cardiac-monitor-receives-ce-mark?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246922
Mar 27, 2024 - Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
0
Abbott (ABT) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2248728/abbott-abt-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2248728
Apr 01, 2024 - Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close.
0
Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval
https://www.zacks.com/stock/news/2249322/abbott-s-abt-i-stat-tbi-cartridge-receives-fda-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249322
Apr 02, 2024 - Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
0
Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks
https://www.zacks.com/commentary/2251046/top-analyst-reports-for-t-mobile-us-abbott-laboratories-palo-alto-networks?cid=CS-ZC-FT-research_daily-2251046
Apr 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).
0
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
https://www.zacks.com/stock/news/2251212/abbott-abt-receives-fda-s-approval-for-the-triclip-teer-system?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251212
Apr 05, 2024 - Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
0